메뉴 건너뛰기




Volumn 92, Issue 3, 2012, Pages 371-383

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

Author keywords

anoikis resistance; EGFR; lung adenocarcinoma; Src; WZ4002

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; NAVITOCLAX; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; WZ 4002;

EID: 84857716200     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.187     Document Type: Article
Times cited : (45)

References (32)
  • 1
    • 67349142163 scopus 로고    scopus 로고
    • A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size
    • Sakuma Y, Okamoto N, Saito H, et al. A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size. Lung Cancer 2009;65:85-90.
    • (2009) Lung Cancer , vol.65 , pp. 85-90
    • Sakuma, Y.1    Okamoto, N.2    Saito, H.3
  • 2
    • 0028057613 scopus 로고
    • Disruption of epithelial cell-matrix interactions induces apoptosis
    • Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626. (Pubitemid 24064472)
    • (1994) Journal of Cell Biology , vol.124 , Issue.4 , pp. 619-626
    • Frisch, S.M.1    Francis, H.2
  • 3
    • 10944223361 scopus 로고    scopus 로고
    • Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis
    • DOI 10.1038/sj.onc.1208091
    • Wei L, Yang Y, Zhang X, et al. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 2004;23:9052-9061. (Pubitemid 40013072)
    • (2004) Oncogene , vol.23 , Issue.56 , pp. 9052-9061
    • Wei, L.1    Yang, Y.2    Zhang, X.3    Yu, Q.4
  • 4
    • 35649025769 scopus 로고    scopus 로고
    • CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma
    • DOI 10.1128/MCB.01246-07
    • Uekita T, Jia L, Narisawa-Saito M, et al. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007;27:7649-7660. (Pubitemid 350033670)
    • (2007) Molecular and Cellular Biology , vol.27 , Issue.21 , pp. 7649-7660
    • Uekita, T.1    Jia, L.2    Narisawa-Saito, M.3    Yokota, J.4    Kiyono, T.5    Sakai, R.6
  • 5
    • 77949863504 scopus 로고    scopus 로고
    • Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src
    • Sakuma Y, Takeuchi T, Nakamura Y, et al. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. J Pathol 2010;220:574-585.
    • (2010) J Pathol , vol.220 , pp. 574-585
    • Sakuma, Y.1    Takeuchi, T.2    Nakamura, Y.3
  • 6
    • 44849112219 scopus 로고    scopus 로고
    • ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
    • Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
    • (2008) Cancer Res , vol.68 , pp. 3421-3428
    • Tse, C.1    Shoemaker, A.R.2    Adickes, J.3
  • 7
    • 65849378710 scopus 로고    scopus 로고
    • Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
    • Cragg MS, Harris C, Strasser A, et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009;9:321-326.
    • (2009) Nat Rev Cancer , vol.9 , pp. 321-326
    • Cragg, M.S.1    Harris, C.2    Strasser, A.3
  • 8
    • 79551599947 scopus 로고    scopus 로고
    • ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis
    • Sakuma Y, Tsunezumi J, Nakamura Y, et al. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep 2011;25:661-667.
    • (2011) Oncol Rep , vol.25 , pp. 661-667
    • Sakuma, Y.1    Tsunezumi, J.2    Nakamura, Y.3
  • 9
    • 35648953299 scopus 로고    scopus 로고
    • Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
    • Cragg MS, Kuroda J, Puthalakath H, et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681-1689.
    • (2007) PLoS Med , vol.4 , pp. 1681-1689
    • Cragg, M.S.1    Kuroda, J.2    Puthalakath, H.3
  • 10
    • 35648965243 scopus 로고    scopus 로고
    • Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas
    • Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas. PLoS Med 2007;4:e294.
    • (2007) PLoS Med , vol.4
    • Gong, Y.1    Somwar, R.2    Politi, K.3
  • 11
    • 33847323129 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in lung cancer
    • Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
    • (2007) Nat Rev Cancer , vol.7 , pp. 169-181
    • Sharma, S.V.1    Bell, D.W.2    Settleman, J.3
  • 12
    • 77958478674 scopus 로고    scopus 로고
    • Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer
    • Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774.
    • (2010) Nat Rev Cancer , vol.10 , pp. 760-774
    • Pao, W.1    Chmielecki, J.2
  • 13
    • 77952105211 scopus 로고    scopus 로고
    • Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
    • Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17: 427-442.
    • (2010) Cancer Cell , vol.17 , pp. 427-442
    • Zhang, B.1    Strauss, A.C.2    Chu, S.3
  • 14
    • 33745243692 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
    • DOI 10.1158/0008-5472.CAN-05-4620
    • Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66: 5542-5548. (Pubitemid 43927102)
    • (2006) Cancer Research , vol.66 , Issue.11 , pp. 5542-5548
    • Song, L.1    Morris, M.2    Bagui, T.3    Lee, F.Y.4    Jove, R.5    Haura, E.B.6
  • 16
    • 67349269541 scopus 로고    scopus 로고
    • The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancerassociated EGF receptor mutants
    • Chung BM, Dimri M, George M, et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancerassociated EGF receptor mutants. Oncogene 2009;28:1821-1832.
    • (2009) Oncogene , vol.28 , pp. 1821-1832
    • Chung, B.M.1    Dimri, M.2    George, M.3
  • 17
    • 72949092456 scopus 로고    scopus 로고
    • Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    • Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-1074.
    • (2009) Nature , vol.462 , pp. 1070-1074
    • Zhou, W.1    Ercan, D.2    Chen, L.3
  • 18
    • 0034024551 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase in DNA damage-response pathway: Implications for radiation oncology
    • DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4
    • Soldatenkov VA, Smulson M. Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. Int J Cancer 2000;90:59-67. (Pubitemid 30253030)
    • (2000) International Journal of Cancer , vol.90 , Issue.2 , pp. 59-67
    • Soldatenkov, V.A.1    Smulson, M.2
  • 19
    • 1542344542 scopus 로고    scopus 로고
    • Agarose Cell Block: Innovated Technique for the Processing of Urine Cytology for Electron Microscopy Examination
    • Mansy SS. Agarose cell block: innovated technique for the processing of urine cytology for electron microscopy examination. Ultrastruct Pathol 2004;28:15-21. (Pubitemid 38299720)
    • (2004) Ultrastructural Pathology , vol.28 , Issue.1 , pp. 15-21
    • Mansy, S.S.1
  • 21
    • 77957273623 scopus 로고    scopus 로고
    • TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
    • Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010;107:15535-15540.
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 15535-15540
    • Yao, Z.1    Fenoglio, S.2    Gao, D.C.3
  • 22
    • 77950809059 scopus 로고    scopus 로고
    • A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
    • Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
    • (2010) Cell , vol.141 , pp. 69-80
    • Sharma, S.V.1    Lee, D.Y.2    Li, B.3
  • 23
    • 70349758510 scopus 로고    scopus 로고
    • Src kinases as therapeutic targets for cancer
    • Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-595.
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 587-595
    • Kim, L.C.1    Song, L.2    Haura, E.B.3
  • 24
    • 77950491674 scopus 로고    scopus 로고
    • Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
    • Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1387-1394.
    • (2010) J Clin Oncol , vol.28 , pp. 1387-1394
    • Haura, E.B.1    Tanvetyanon, T.2    Chiappori, A.3
  • 25
    • 38949107292 scopus 로고    scopus 로고
    • EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: Implications in targeting therapy
    • DOI 10.1038/sj.onc.1210684, PII 1210684
    • Fu YN, Yeh CL, Cheng HH, et al. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 2008;27:957-965. (Pubitemid 351225379)
    • (2008) Oncogene , vol.27 , Issue.7 , pp. 957-965
    • Fu, Y.-N.1    Yeh, C.-L.2    Cheng, H.H.-Y.3    Yang, C.-H.4    Tsai, S.-F.5    Huang, S.-F.6    Chen, Y.-R.7
  • 26
    • 72949119124 scopus 로고    scopus 로고
    • Integrins in cancer: Biological implications and therapeutic opportunities
    • Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
    • (2010) Nat Rev Cancer , vol.10 , pp. 9-22
    • Desgrosellier, J.S.1    Cheresh, D.A.2
  • 27
    • 79953740723 scopus 로고    scopus 로고
    • Malignant pleural effusion from lung adenocarcinoma treated by gefitinib
    • Kubo A, Koh Y, Kawaguchi T, et al. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. Intern Med 2011;50: 745-748.
    • (2011) Intern Med , vol.50 , pp. 745-748
    • Kubo, A.1    Koh, Y.2    Kawaguchi, T.3
  • 28
    • 77952502408 scopus 로고    scopus 로고
    • A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth
    • Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583-594.
    • (2010) Cell , vol.141 , pp. 583-594
    • Roesch, A.1    Fukunaga-Kalabis, M.2    Schmidt, E.C.3
  • 29
    • 79959916680 scopus 로고    scopus 로고
    • MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
    • Fan W, Tang Z, Yin L, et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 2011;71:4494-4505.
    • (2011) Cancer Res , vol.71 , pp. 4494-4505
    • Fan, W.1    Tang, Z.2    Yin, L.3
  • 30
    • 79961218347 scopus 로고    scopus 로고
    • Asymmetric cancer cell division regulated by AKT
    • Dey-Guha I, Wolfer A, Yeh AC, et al. Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci USA 2011;108:12845-12850.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 12845-12850
    • Dey-Guha, I.1    Wolfer, A.2    Yeh, A.C.3
  • 31
    • 34748840882 scopus 로고    scopus 로고
    • Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
    • DOI 10.1158/1535-7163.MCT-06-0761
    • Edwards A, Li J, Atadja P, et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007;6:2515-2524. (Pubitemid 47480417)
    • (2007) Molecular Cancer Therapeutics , vol.6 , Issue.9 , pp. 2515-2524
    • Edwards, A.1    Li, J.2    Atadja, P.3    Bhalla, K.4    Haura, E.B.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.